JP2015518904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518904A5 JP2015518904A5 JP2015516260A JP2015516260A JP2015518904A5 JP 2015518904 A5 JP2015518904 A5 JP 2015518904A5 JP 2015516260 A JP2015516260 A JP 2015516260A JP 2015516260 A JP2015516260 A JP 2015516260A JP 2015518904 A5 JP2015518904 A5 JP 2015518904A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- alkoxy
- halo
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 66
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 56
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 125000003282 alkyl amino group Chemical group 0.000 claims description 50
- 125000005843 halogen group Chemical group 0.000 claims description 45
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 42
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 40
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 35
- 125000001424 substituent group Chemical group 0.000 claims description 35
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 23
- 125000001589 carboacyl group Chemical group 0.000 claims description 20
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 18
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 18
- 230000009385 viral infection Effects 0.000 claims description 17
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 16
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000003003 spiro group Chemical group 0.000 claims description 10
- 125000005549 heteroarylene group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- -1 cyano, hydroxy Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 4
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000001490 Dengue Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 201000005805 Murray valley encephalitis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 206010041896 St. Louis Encephalitis Diseases 0.000 claims description 2
- 229940124615 TLR 7 agonist Drugs 0.000 claims description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 2
- 201000006449 West Nile encephalitis Diseases 0.000 claims description 2
- 208000003152 Yellow Fever Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 229960000517 boceprevir Drugs 0.000 claims description 2
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
- 229960002063 sofosbuvir Drugs 0.000 claims description 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229960002935 telaprevir Drugs 0.000 claims description 2
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 claims description 2
- 108010017101 telaprevir Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 1
- 241000907316 Zika virus Species 0.000 claims 1
- 0 CC(CCCC(NC(C(C(C)[C@](C)C(N1N[C@]2CCC1)=O)=O)=C(C)C)=O)C=C*(C(C1)N)=CC=C1[C@@](C)*C2=O Chemical compound CC(CCCC(NC(C(C(C)[C@](C)C(N1N[C@]2CCC1)=O)=O)=C(C)C)=O)C=C*(C(C1)N)=CC=C1[C@@](C)*C2=O 0.000 description 23
- 150000002148 esters Chemical class 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- LURLDFUOIKEELM-NPKGIASISA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CCC(CC1)(F)F)c2)=O)=O)=O)NC1=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CCC(CC1)(F)F)c2)=O)=O)=O)NC1=O LURLDFUOIKEELM-NPKGIASISA-N 0.000 description 2
- QTYULVDUFLCFOF-NLCONRCSSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C3(CC4)CCN4C(OC(C)(C)C)=O)ccc2cc1)=O)=O)=O)NC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C3(CC4)CCN4C(OC(C)(C)C)=O)ccc2cc1)=O)=O)=O)NC3=O QTYULVDUFLCFOF-NLCONRCSSA-N 0.000 description 2
- VLMXFTVJDLZBJC-OMCJITFHSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C34CCNCC3)ccc2cc1)=O)=O)=O)NC4=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C34CCNCC3)ccc2cc1)=O)=O)=O)NC4=O VLMXFTVJDLZBJC-OMCJITFHSA-N 0.000 description 2
- ZCXNIEBUCYJLPK-AOLLOGBZSA-N CCC[C@](CCOCC)(/C=C/c1ccc(ccc([C@@H](C)OC([C@H](CCC2)NN2C([C@H](C)NC([C@H](C(C)C)N2)=O)=O)=O)n3)c3c1)C2=O Chemical compound CCC[C@](CCOCC)(/C=C/c1ccc(ccc([C@@H](C)OC([C@H](CCC2)NN2C([C@H](C)NC([C@H](C(C)C)N2)=O)=O)=O)n3)c3c1)C2=O ZCXNIEBUCYJLPK-AOLLOGBZSA-N 0.000 description 2
- CHEQYRNYWVIYEI-KGCYQTSASA-N C[C@H](c1nc2cc(/C=C/C(C)(C)C(N[C@@H](/C(/C)=C/C)C(N[C@@H](C)C(N3N[C@H]4CCC3)=O)=O)=O)ccc2cc1)OC4=O Chemical compound C[C@H](c1nc2cc(/C=C/C(C)(C)C(N[C@@H](/C(/C)=C/C)C(N[C@@H](C)C(N3N[C@H]4CCC3)=O)=O)=O)ccc2cc1)OC4=O CHEQYRNYWVIYEI-KGCYQTSASA-N 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- QBNHNFSXZUANPX-PFZJTCDASA-N CC([C@@H](C(N[C@@H](C)C(N(CCC1)NC1C(O[C@H](C)C1C=C(C=C(/C=C/C2)N=C3)C3=CC1)=O)=O)=O)NC2=O)O Chemical compound CC([C@@H](C(N[C@@H](C)C(N(CCC1)NC1C(O[C@H](C)C1C=C(C=C(/C=C/C2)N=C3)C3=CC1)=O)=O)=O)NC2=O)O QBNHNFSXZUANPX-PFZJTCDASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657550P | 2012-06-08 | 2012-06-08 | |
| US61/657,550 | 2012-06-08 | ||
| PCT/US2013/044826 WO2013185103A1 (en) | 2012-06-08 | 2013-06-07 | Macrocyclic inhibitors of flaviviridae viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518904A JP2015518904A (ja) | 2015-07-06 |
| JP2015518904A5 true JP2015518904A5 (OSRAM) | 2016-07-28 |
| JP6209601B2 JP6209601B2 (ja) | 2017-10-04 |
Family
ID=48692655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516260A Expired - Fee Related JP6209601B2 (ja) | 2012-06-08 | 2013-06-07 | フラビウイルス科ウイルスの大環状阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9145441B2 (OSRAM) |
| EP (1) | EP2861604B1 (OSRAM) |
| JP (1) | JP6209601B2 (OSRAM) |
| KR (1) | KR20150040265A (OSRAM) |
| CN (1) | CN104703991B (OSRAM) |
| AU (1) | AU2013270672B2 (OSRAM) |
| BR (1) | BR112014030630A2 (OSRAM) |
| CA (1) | CA2875692A1 (OSRAM) |
| EA (1) | EA026235B1 (OSRAM) |
| ES (1) | ES2624223T3 (OSRAM) |
| HK (1) | HK1211285A1 (OSRAM) |
| IL (1) | IL236005A0 (OSRAM) |
| IN (1) | IN2014MN02652A (OSRAM) |
| MX (1) | MX2014014766A (OSRAM) |
| NZ (2) | NZ703040A (OSRAM) |
| PL (1) | PL2861604T3 (OSRAM) |
| PT (1) | PT2861604T (OSRAM) |
| SG (1) | SG11201408047XA (OSRAM) |
| SI (1) | SI2861604T1 (OSRAM) |
| WO (1) | WO2013185103A1 (OSRAM) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| ES2656087T3 (es) * | 2012-06-08 | 2018-02-23 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de virus Flaviviridae |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US20170008785A1 (en) * | 2015-07-07 | 2017-01-12 | Nch Corporation | System and Method for Treating Water with a Biological Based Biocide |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EP3463469B1 (en) | 2016-05-27 | 2023-12-13 | Gilead Sciences, Inc. | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| BR112019015231A2 (pt) | 2017-01-25 | 2020-04-14 | Basf Se | processos para a preparação de compostos e compostos |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| US11229638B2 (en) | 2017-08-22 | 2022-01-25 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| GEP20227359B (en) | 2017-12-13 | 2022-03-10 | Lupin Ltd | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019201848A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CA3103987C (en) | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| KR102629921B1 (ko) | 2018-07-06 | 2024-01-31 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| WO2021091956A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| US12110305B2 (en) | 2020-08-07 | 2024-10-08 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| WO2022058344A1 (en) | 2020-09-18 | 2022-03-24 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114634421A (zh) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | 一种达沙替尼中间体的制备方法 |
| EP4562017A1 (en) | 2022-07-29 | 2025-06-04 | Pfizer Inc. | Novel acc inhibitors |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| JP5044823B2 (ja) | 2005-06-16 | 2012-10-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ａ２ｂアデノシンレセプターアンタゴニストのプロドラッグ |
| WO2006138507A1 (en) * | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
| EP2011786A1 (en) | 2007-07-05 | 2009-01-07 | Laboratorios del Dr. Esteve S.A. | Indane-amine derivatives, their preparation and use as medicaments |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| JP5309159B2 (ja) | 2008-01-09 | 2013-10-09 | コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション | バキュロウイルスを利用したワクチン |
| US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| BRPI0923393B1 (pt) * | 2008-12-23 | 2018-06-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | "processos para preparar um inibidor de protease de hcv macrocíclico e intermediários e uso". |
| US9296698B2 (en) | 2009-11-23 | 2016-03-29 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| US8513298B2 (en) * | 2010-01-15 | 2013-08-20 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| WO2012040040A1 (en) * | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| AR084217A1 (es) * | 2010-12-10 | 2013-05-02 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| ES2656087T3 (es) * | 2012-06-08 | 2018-02-23 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de virus Flaviviridae |
| NZ701721A (en) | 2012-06-08 | 2016-03-31 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4-arylthiazole compounds and their salts |
-
2013
- 2013-06-07 PT PT137312039T patent/PT2861604T/pt unknown
- 2013-06-07 US US13/913,259 patent/US9145441B2/en not_active Ceased
- 2013-06-07 WO PCT/US2013/044826 patent/WO2013185103A1/en not_active Ceased
- 2013-06-07 CA CA2875692A patent/CA2875692A1/en not_active Abandoned
- 2013-06-07 MX MX2014014766A patent/MX2014014766A/es unknown
- 2013-06-07 BR BR112014030630A patent/BR112014030630A2/pt not_active Application Discontinuation
- 2013-06-07 SI SI201330574A patent/SI2861604T1/sl unknown
- 2013-06-07 HK HK15111999.1A patent/HK1211285A1/xx unknown
- 2013-06-07 JP JP2015516260A patent/JP6209601B2/ja not_active Expired - Fee Related
- 2013-06-07 EP EP13731203.9A patent/EP2861604B1/en not_active Not-in-force
- 2013-06-07 EA EA201492209A patent/EA026235B1/ru not_active IP Right Cessation
- 2013-06-07 IN IN2652MUN2014 patent/IN2014MN02652A/en unknown
- 2013-06-07 CN CN201380039194.XA patent/CN104703991B/zh not_active Expired - Fee Related
- 2013-06-07 KR KR1020157000171A patent/KR20150040265A/ko not_active Withdrawn
- 2013-06-07 AU AU2013270672A patent/AU2013270672B2/en not_active Ceased
- 2013-06-07 ES ES13731203.9T patent/ES2624223T3/es active Active
- 2013-06-07 PL PL13731203T patent/PL2861604T3/pl unknown
- 2013-06-07 NZ NZ703040A patent/NZ703040A/en not_active IP Right Cessation
- 2013-06-07 SG SG11201408047XA patent/SG11201408047XA/en unknown
- 2013-06-07 NZ NZ724503A patent/NZ724503A/en not_active IP Right Cessation
-
2014
- 2014-11-30 IL IL236005A patent/IL236005A0/en unknown
-
2015
- 2015-08-07 US US14/821,458 patent/US9512175B2/en not_active Expired - Fee Related
-
2017
- 2017-09-25 US US15/715,080 patent/USRE47334E1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518904A5 (OSRAM) | ||
| JP2015525221A5 (OSRAM) | ||
| JP2015525220A5 (OSRAM) | ||
| SI2861601T1 (en) | Macrocyclic flaviviridae virus inhibitors | |
| JP2014503516A5 (OSRAM) | ||
| RU2468029C2 (ru) | Ингибиторы hcv ns3 протеазы | |
| WO2012092484A3 (en) | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | |
| CN115215914A (zh) | 核苷类似物及其用途 | |
| JP2013538235A5 (OSRAM) | ||
| JP2012504126A5 (OSRAM) | ||
| ES2561888T3 (es) | Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae | |
| CA2389745A1 (en) | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues | |
| JP2017505314A5 (OSRAM) | ||
| JP2008531704A5 (OSRAM) | ||
| JP2007534662A5 (OSRAM) | ||
| JP2013514359A5 (OSRAM) | ||
| RU2015123641A (ru) | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний | |
| JP2013521279A5 (OSRAM) | ||
| JP2012523415A5 (OSRAM) | ||
| JP2012513479A5 (OSRAM) | ||
| JP2010514768A5 (OSRAM) | ||
| JP2011523651A5 (OSRAM) | ||
| RU2011133900A (ru) | Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с | |
| JP2016503800A5 (OSRAM) | ||
| MXPA04007876A (es) | Analogos de nucleosido fluorado modificados. |